Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

HMENA isoforms regulate cancer intrinsic Type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC [RNA-seq]

ABSTRACT: Understanding how cancer signaling pathways promote an immunosuppressive program which sustains acquired or primary resistance to immune checkpoint blockade (ICB) is a crucial step in improving immunotherapy efficacy. Among the pathways that can affect ICB response is the IFN pathway that may be detrimental rather than beneficial. Effects of hMENA11a down-regulation were tested by RNA-Seq, ATAC-Seq, flow cytometry and biochemical assays. ICB treated patient tumor tissues were profiled by Nanostring IO 360 Panel enriched with hMENA custom probes.

ORGANISM(S): Homo sapiens

PROVIDER: GSE224216 | GEO | 2023/08/30

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

hMENA isoforms regulate cancer intrinsic Type I IFN signaling and extrinsic mechanisms of resistance to immune checkpoint blockade in NSCLC [ATAC-seq]

Project description:Understanding how cancer signaling pathways promote an immunosuppressive program which sustains acquired or primary resistance to immune checkpoint blockade (ICB) is a crucial step in improving immunotherapy efficacy. Among the pathways that can affect ICB response is the IFN pathway that may be detrimental rather than beneficial. Effects of hMENA11a down-regulation were tested by RNA-Seq, ATAC-Seq, flow cytometry and biochemical assays. ICB treated patient tumor tissues were profiled by Nanostring IO 360 Panel enriched with hMENA custom probes.

2023-08-30 | GSE224246 | GEO

Clonal tracing reveals the contribution of both cancer-intrinsic and -extrinsic mechanisms to the heterogeneity of responses to immune checkpoint blockade [RNA-seq_ICB]

Project description:Although multiple studies have investigated the biomarkers of response to immune checkpoint blockade (ICB), the significance of each biomarker varies across clinical cohorts independent of cancer type. It remains unclear whether primary ICB response and resistance is encoded in the cancer cells (cancer-intrinsic) or driven by the immune microenvironment unique to each host (cancer-extrinsic). To answer this question, we established a unique mouse system that utilizes clonal tracing and mathematical modeling to uncouple the cancer-intrinsic and -extrinsic mechanisms of ICB resistance. We found that tumors with the same clonal constitution show heterogeneous ICB response in different hosts. Primary resistance is associated with the cancer-extrinsic immune microenvironment rather than proliferation of intrinsically ICB-resistant cancer cells. Instead, pre-existing cancer-intrinsic ICB-resistant clones with distinct transcriptional and epigenetic profiles were enriched in responders. We further identified two gene expression signatures associated with cancer-intrinsic resistance, including increased interferon response genes and glucocorticoid response genes. Our findings are supported by experiments in another mouse model and clinical data from multiple ICB treatment cohorts. Our study emphasizes the importance of optimal microenvironment in cancer immunotherapy, and implicates the value of immunotherapy biomarkers that account for both cancer-intrinsic and -extrinsic mechanisms of resistance.

2020-07-01 | GSE139475 | GEO

Clonal tracing reveals the contribution of both cancer-intrinsic and -extrinsic mechanisms to the heterogeneity of responses to immune checkpoint blockade [RNA-seq]

2020-07-01 | GSE139474 | GEO

Clonal tracing reveals the contribution of both cancer-intrinsic and -extrinsic mechanisms to the heterogeneity of responses to immune checkpoint blockade [ATAC-seq]

2020-07-01 | GSE139473 | GEO

Gene expression of human angiosarcoma

Project description:Gene expression profiling of human angiosarcoma samples was performed using the NanoString Human nCounter PanCancer IO 360 Panel

2023-05-03 | GSE226338 | GEO

Gene expression of human angiosarcoma and correlation with treatment outcomes

Project description:Gene expression profiling of human angiosarcoma samples was performed using the NanoString Human nCounter PanCancer IO 360 Panel

2020-12-01 | GSE162370 | GEO

Transcriptomic analyses of NF1-mutant melanoma

Project description:RNA analysis of 770 genes (Pan Cancer IO 360) related to the tumor microenvironment on NF1-MUT and matched NF1-WT samples for reference.

2022-05-12 | GSE202806 | GEO

Spatial analysis reveals distinct immune phenotypes and tertiary lymphoid structure-like aggregates in pediatric acute myeloid leukemia [Nanostring PanCancer IO 360]

Project description:Comparison of immune-infiltrated bone marrow samples (n=6) with immune-depleted bone marrow samples (n=17) of pediatric acute myeloid leukemia patients using the Nanostring PanCancer IO 360 panel.

2024-08-27 | GSE228481 | GEO

Mammary Tumor-Derived Transplants as Breast Cancer Models to Evaluate Tumor-Immune Interactions and Therapeutic Responses

Project description:To investigate mTDT transcriptional features using the Nanostring pancancer io 360 gene expression panel that consists of 770 unique genes involved in the interplay between the tumor, microenvironment and immune response.

2021-12-01 | GSE152403 | GEO

CCA NanoString data (60CCA)

Project description:Raw .RCC files for NanoString. nCounter PanCancer IO 360 Panel was used

| EGAD00010002612 | EGA